CytomX Therapeutics Inc at H.C. Wainwright BioConnect Investor Conference Transcript
Hey, everyone. My name is Mitchell Kapoor. I'm a senior biotech analyst here at H.C. Wainwright. It's my pleasure to welcome you to the BioConnect Conference.
Joining me today is Sean McCarthy, CEO of CytomX. It's an exciting time for CytomX, and I'm glad that he could join me. So maybe, Sean, if you could give us an overview of the CytomX pipeline, what you're doing today, and just how you're differentiated.
Yeah. Thanks, Mitch. Thanks for the invitation. Pleasure to be here. So CytomX Therapeutics is focused on a concept that when we look at the current evolution of biologic therapies in oncology, there's an increasing move to more and more potent formats: so immunotherapies, antibody drug conjugates, bispecifics, and cytokines as examples. And what we've observed, I think, as a field, is that as we've tried to drive the potency of these agents, it can be difficult to separate the potency from the toxicity.
So our thesis at
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
